- Home
- AQB vs ADXN Comparison
AQB vs ADXN Comparison
Compare AQB & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- ADXN
- Stock Information
- Founded
- AQB 1991
- ADXN 2002
- Country
- AQB United States
- ADXN Switzerland
- Employees
- AQB N/A
- ADXN N/A
- Industry
- AQB
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- ADXN Health Care
- Exchange
- AQB Nasdaq
- ADXN Nasdaq
- Market Cap
- AQB 7.1M
- ADXN 8.5M
- IPO Year
- AQB N/A
- ADXN N/A
- Fundamental
- Price
- AQB $1.73
- ADXN $8.53
- Analyst Decision
- AQB
- ADXN
- Analyst Count
- AQB 0
- ADXN 0
- Target Price
- AQB N/A
- ADXN N/A
- AVG Volume (30 Days)
- AQB 441.0K
- ADXN 6.9K
- Earning Date
- AQB 11-04-2025
- ADXN 11-21-2025
- Dividend Yield
- AQB N/A
- ADXN N/A
- EPS Growth
- AQB N/A
- ADXN N/A
- EPS
- AQB N/A
- ADXN N/A
- Revenue
- AQB N/A
- ADXN $210,347.00
- Revenue This Year
- AQB N/A
- ADXN $86.57
- Revenue Next Year
- AQB N/A
- ADXN N/A
- P/E Ratio
- AQB N/A
- ADXN N/A
- Revenue Growth
- AQB N/A
- ADXN N/A
- 52 Week Low
- AQB $0.47
- ADXN $6.51
- 52 Week High
- AQB $2.95
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- AQB 49.40
- ADXN 47.00
- Support Level
- AQB $1.67
- ADXN $8.52
- Resistance Level
- AQB $1.97
- ADXN $9.51
- Average True Range (ATR)
- AQB 0.27
- ADXN 0.55
- MACD
- AQB -0.07
- ADXN -0.10
- Stochastic Oscillator
- AQB 4.69
- ADXN 7.14
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.